289 related articles for article (PubMed ID: 23624828)
1. Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer.
Li ZH; Zhang XB; Han XQ; Feng CR; Wang FS; Wang PG; Shen J; Shi YK
Oncol Rep; 2013 Jul; 30(1):499-505. PubMed ID: 23624828
[TBL] [Abstract][Full Text] [Related]
2. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
Patra N; De U; Kim TH; Lee YJ; Ahn MY; Kim ND; Yoon JH; Choi WS; Moon HR; Lee BM; Kim HS
Biomed Pharmacother; 2013 Jun; 67(5):407-15. PubMed ID: 23583193
[TBL] [Abstract][Full Text] [Related]
3. Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest.
Yang H; Xu W; Li Y; Lan P; Zhang J; Zhang Y; Zhang C
Anticancer Drugs; 2014 Aug; 25(7):767-77. PubMed ID: 24686006
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
5. Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
Park KC; Kim SW; Park JH; Song EH; Yang JW; Chung HJ; Jung HJ; Suh JS; Kwon HJ; Choi SH
Cancer Sci; 2011 Feb; 102(2):343-50. PubMed ID: 21159061
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
[TBL] [Abstract][Full Text] [Related]
7. A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells.
Yang L; Liang Q; Shen K; Ma L; An N; Deng W; Fei Z; Liu J
Biomed Pharmacother; 2015 Apr; 71():70-8. PubMed ID: 25960218
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
Hrzenjak A; Moinfar F; Kremser ML; Strohmeier B; Petru E; Zatloukal K; Denk H
Mol Cancer; 2010 Mar; 9():49. PubMed ID: 20202195
[TBL] [Abstract][Full Text] [Related]
10. Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
Zhang Y; Feng J; Jia Y; Wang X; Zhang L; Liu C; Fang H; Xu W
J Med Chem; 2011 Apr; 54(8):2823-38. PubMed ID: 21476600
[TBL] [Abstract][Full Text] [Related]
11. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
[TBL] [Abstract][Full Text] [Related]
12. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
13. Potent in vivo anti-breast cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTV/c-Neu mice.
Joung KE; Min KN; An JY; Kim DK; Kong G; Sheen YY
Cancer Res; 2006 May; 66(10):5394-402. PubMed ID: 16707467
[TBL] [Abstract][Full Text] [Related]
14. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
15. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
16. Effects of trichostatin A, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells.
Park H; Lee YJ; Kim TH; Lee J; Yoon S; Choi WS; Myung CS; Kim HS
Int J Mol Med; 2008 Nov; 22(5):605-11. PubMed ID: 18949380
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.
Kim DH; Lee J; Kim KN; Kim HJ; Jeung HC; Chung HC; Kwon HJ
Biochem Biophys Res Commun; 2007 Apr; 356(1):233-8. PubMed ID: 17353008
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer cells are arrested at different phases of the cell cycle following the re-expression of ARHI.
Zuo X; Qin Y; Zhang X; Ning Q; Shao S; Luo M; Yuan N; Huang S; Zhao X
Oncol Rep; 2014 May; 31(5):2358-64. PubMed ID: 24676336
[TBL] [Abstract][Full Text] [Related]
19. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.
Hsi LC; Xi X; Lotan R; Shureiqi I; Lippman SM
Cancer Res; 2004 Dec; 64(23):8778-81. PubMed ID: 15574791
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities.
Zhang Y; Fang H; Feng J; Jia Y; Wang X; Xu W
J Med Chem; 2011 Aug; 54(15):5532-9. PubMed ID: 21714538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]